Drug & intervention

Rebif

RxCUI 228271

Clinical trials11
Recruiting0
Related conditions5
Synonyms1

Understanding this RxNorm record

RxNorm identifiers distinguish ingredients, specific strengths, dose forms, and branded products. They help connect equivalent terminology across data sources; an RxNorm entry does not by itself establish that a product is currently marketed, approved for a particular use, or appropriate for an individual.

Clinical-trial associations reflect registry-reported intervention names and verified mappings where available. A medication listed in a trial may be investigational for that condition. Consult the original study record and official prescribing information for indications and safety details.

Terminology source: National Library of Medicine RxNorm. Trial source: ClinicalTrials.gov.

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Rebif

Wikidata Q29006409 ↗
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

11 shown
MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS)NCT02949908 · 2017-02-09
TERMINATED
Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®NCT02823951 · 2016-02-01
COMPLETED
Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™NCT02254304 · 2014-12-31
COMPLETED
Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy VolunteersNCT02269930 · 2014-10-01
COMPLETED
Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) PatientsNCT01601119 · 2012-01-01
COMPLETED
Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot TrialNCT01085318 · 2010-06-30
COMPLETED
A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times WeeklyNCT01198132 · 2009-11-01
COMPLETED
Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or RebifNCT00317941 · 2006-03-01
COMPLETED
Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) SubjectsNCT00101959 · 2004-11-01
WITHDRAWN
EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple SclerosisNCT00137176 · 2004-10-01
COMPLETED
Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMSNCT00202995 · 2004-07-01
TERMINATED

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.